We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > FSD

News List

FSD Pharma Announces Termination of FSD-201 Phase 2 Clinical Trial firstwordpharma
August 25, 2021
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "FSD") announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide ("PEA"), or FSD-201, for use in treating COVID-19.
Therapix Biosciences Terminates FSD Acquisition Letter of Intent americanpharmaceuticalreview
December 24, 2018
Therapix Biosciences, a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments.....
M Pharmaceutical to develop new topical drug product for FSD pharmaceutical-technology
January 17, 2017
Canadian-headquartered M Pharmaceutical has announced plans to continue advancing the development of a topical drug product as part of its planned acquisition of 40 J's.